Aquestive Therapeutics Elects Richard J. Daly to Board

What Happened

• Aquestive Therapeutics, Inc. (AQST) announced on September 29, 2026 (8-K filed) that its Board elected Richard J. Daly as a director, effective October 14, 2026. Mr. Daly will serve as a Class I director with a term expiring at the Company’s 2028 Annual Meeting of Stockholders.
• The Board increased its size from seven to eight directors; following Mr. Daly’s election, seven of the eight directors will be independent. The Board determined Mr. Daly qualifies as an independent director under Nasdaq rules.

Key Details

• Election date filed: September 29, 2026; effective October 14, 2026.
• Term: Class I director, term expires at the 2028 Annual Meeting.
• Equity award: initial grant of 57,000 stock options under the 2018 Equity Incentive Plan. Options to be granted the second full trading day after the Company’s next public earnings release (“Grant Date”), exercise price = closing market price on Nasdaq on the Grant Date, vesting in three annual one‑third installments starting one year after the Grant Date.
• Selection process: recommended by the Nominating and Corporate Governance Committee after a formal search with an independent executive search firm; no special arrangements or family relationships reported.

Why It Matters

• Board change: Adding an independent director and increasing board size can affect corporate governance and oversight — important for investors monitoring management accountability and board composition.
• Compensation/dilution: The 57,000 stock options represent potential future dilution if exercised; terms tie exercise price to market price at the Grant Date and include standard multi‑year vesting.
• Timing: Mr. Daly’s appointment is effective Oct 14, 2026 and the option grant timing ties to the Company’s next earnings release, so investors can watch upcoming filings and disclosures for the exact grant date and further details.